The oxoglutarate receptor 1 (OXGR1) modulates pressure overload-induced cardiac hypertrophy in mice.
The G-protein-coupled receptors (GPCRs) family of proteins play essential roles in the heart, including in the regulation of cardiac hypertrophy. One member of this family, the oxoglutarate receptor 1 (OXGR1), may have a crucial role in the heart because it acts as a receptor for α-ketoglutarate, a metabolite that is elevated in heart failure patients. OXGR1 is expressed in the heart but its precise function during cardiac pathophysiological process is unknown. Here we used both in vivo and in vitro approaches to investigate the role of OXGR1 in cardiac hypertrophy. Genetic ablation of Oxgr1 in mice (OXGR1-/-) resulted in a significant increase in hypertrophy following transverse aortic constriction (TAC). This was accompanied by reduction in contractile function as indicated by cardiac fractional shortening and ejection fraction. Conversely, adenoviral mediated overexpression of OXGR1 in neonatal rat cardiomyocytes significantly reduced phenylephrine-induced cardiomyocyte hypertrophy, a result that was consistent with the in vivo data. Using a combination of yeast two hybrid screening and phospho-antibody array analysis we identified novel interacting partner and downstream signalling pathway that might be regulated by the OXGR1. First, we found that OXGR1 forms a molecular complex with the COP9 signalosome complex subunit 5 (CSN5). Secondly, we observed that the STAT3 signalling pathway was upregulated in OXGR1-/-hearts. Since CSN5 interacts with TYK2, a major upstream regulator of STAT3, OXGR1 might regulate the pro-hypertrophic STAT3 pathway via interaction with the CSN5-TYK2 complex. In conclusion, our study has identified OXGR1 as a novel regulator of pathological hypertrophy via the regulation of the STAT3. Identification of molecules that can specifically activate or inhibit this receptor may be very useful in the development of novel therapeutic approach for pathological cardiac hypertrophy.
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Ameh
A
Omede
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Min
M
Zi
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Sukhpal
S
Prehar
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Arfa
A
Maqsood
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Nicholas
N
Stafford
Keele Cardiovascular Research Group, Institute of Science and Technology in Medicine, Keele University, Stoke-on-Trent, UK.
Mamas
M
Mamas
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.
Elizabeth
E
Cartwright
Division of Cardiovascular Sciences, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK. Electronic address: delvac.oceandy@manchester.ac.uk.
Delvac
D
Oceandy
D000818:Animals; D001011:Aorta; D000075686:COP9 Signalosome Complex; D006332:Cardiomegaly / Q000000981:diagnostic imaging / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002460:Cell Line; D003251:Constriction, Pathologic; D004195:Disease Models, Animal; D004452:Echocardiography; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D010447:Peptide Hydrolases / Q000378:metabolism; D011312:Pressure; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000235:genetics / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D020798:Two-Hybrid System Techniques; D015854:Up-Regulation
D000075686:COP9 Signalosome Complex; D047908:Intracellular Signaling Peptides and Proteins; D010447:Peptide Hydrolases; D018048:Receptors, Purinergic P2; D050796:STAT3 Transcription Factor; C486887:OXGR1 protein, mouse; C494087:Stat3 protein, mouse; C501490:Cops5 protein, mouse
Cardiac hypertrophy; GPCRs; OXGR1; Pressure overload; STAT3
J Biol Chem. 1999 Nov 5;274(45):32507-11
10542297
Circ Res. 2011 Jul 8;109 (2):217-30
21737817
Plant Sci. 2014 Jul;224:54-61
24908506
Nature. 2004 May 13;429(6988):188-93
15141213
Nature. 2014 Nov 20;515(7527):431-5
25383517
Genomics. 2006 Sep;88(3):263-73
16753280
N Engl J Med. 2008 Mar 27;358(13):1370-80
18367740
J Mol Cell Cardiol. 2006 Apr;40(4):562-9
16483597
Heart Fail Rev. 2011 Jan;16(1):35-47
20407820
Br J Pharmacol. 2010 Jul;160(6):1273-92
20590619
J Biol Chem. 2014 Aug 29;289(35):24275-88
25035424
J Clin Invest. 2008 Oct;118(10):3503-12
18769631
J Biol Chem. 2013 Apr 19;288(16):10967-72
23504326
Circ Heart Fail. 2013 May;6(3):606-19
23616602
Nat Rev Mol Cell Biol. 2006 Aug;7(8):589-600
16936699
J Biol Chem. 2004 May 7;279(19):19790-9
15001573
Open Heart. 2015 Apr 10;2(1):e000222
25893103
EMBO Rep. 2001 Feb;2(2):96-101
11258719
Nat Commun. 2016 Mar 29;7:11074
27020607
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):315-9
10618415
J Biol Chem. 2013 Oct 25;288(43):30969-79
24043623
Expert Rev Cardiovasc Ther. 2006 May;4(3):417-32
16716102
Genes Cells. 2009 Nov;14(11):1209-25
19849719